NRIX vs DMRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NRIX · Nurix Therapeutics$12.85 ▼ 5.51%
DMRA · Damora Therapeutics$23.22 ▼ 4.44%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NRIX -25.1%
- DMRA +42.4%
Head to head
| Metric | NRIX | DMRA |
|---|---|---|
| Price | $12.85 | $23.22 |
| Change today | ▼ 5.51% | ▼ 4.44% |
| Market cap | $1.40B | $1.44B |
| Return, 3 months | -51.1% | -23.4% |
| Return, year to date | -32.3% | +0.9% |
| Return, 1 year | -23.3% | +38.5% |
| P/E (TTM) | 5.3 | 13.6 |
| P/B | 1.4 | 3.9 |
| P/E percentile vs own 5y | 98th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +8,426.3% | – |
| Net profit growth (YoY) | +736.2% | -921.1% |
| Gross margin | – | – |
| Operating margin | 41.3% | – |
| Net margin | 42.0% | – |
| Return on equity | 44.0% | -156.6% |
| Analyst target vs. price | +174.9% | +101.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 21 | 54 |
| 30-day volatility | 149.6% | 61.9% |
| Max drawdown, 1 year | -53.8% | -46.9% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DMRA is the largest of the group by market value.
- DMRA has returned the most over the past year.
- NRIX carries the lowest trailing P/E.
- DMRA has been the calmest stock over the last 30 days.